We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes. Their first offering, PredictImmune-CD, will be in the field of the inflammatory bowel disease.